Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BNT 113

Drug Profile

BNT 113

Alternative Names: BNT-113; E6/E7 RNA(LIP); HPV Anti-CD40 RNA Vaccine; HPV mRNA vaccine; RBLO 15.1(LIP)/RBLO 16.1(LIP)

Latest Information Update: 19 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNTech
  • Developer BioNTech; University Hospital Southampton NHS Foundation Trust
  • Class Cancer vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cervical cancer; Head and neck cancer; Penile cancer

Most Recent Events

  • 07 Nov 2019 BioNTech plans a phase II trial in HPV-positive Head and neck cancer, in the second half of 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top